Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

December 31, 2002

Study Completion Date

August 31, 2005

Conditions
Esophageal CancerGastric Cancer
Interventions
DRUG

irinotecan hydrochloride

"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."

DRUG

paclitaxel

"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."

Trial Locations (4)

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

60611-3013

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

97201-3098

OHSU Cancer Institute, Portland

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00020761 - Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | Biotech Hunter | Biotech Hunter